Skip to main content

2 Result(s)

within Raymond C. Wadlow Remove this filter Medicine & Public Health Remove this filter

and

  1. No Access

    Article

    A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer

    Subsets of esophagogastric (EG) cancers harbor genetic abnormalities, including amplification of HER2, MET, or FGFR2 or mutations in PIK3CA, EGFR, or BRAF. Ganetespib which is a novel triazolone heterocyclic i...

    Lipika Goyal, Surendra Pal Chaudhary, Eunice L. Kwak… in Investigational New Drugs (2020)

  2. No Access

    Article

    A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma

    Background Ganetespib (STA-9090) is an Hsp90 inhibitor that downregulates VEGFR, c-MET, HER2, IGF-IR, EGFR, and other Hsp90 client proteins involved in hepatocarcinogenesis, thereby making it an ...

    Lipika Goyal, Raymond C. Wadlow, Lawrence S. Blaszkowsky… in Investigational New Drugs (2015)